IBM's Nanostack Chip Sparks a Rally, but the Real Test Is Whether Software Can Outrun Consulting's Sickness

IBM shares surged nearly 5% on Friday to close at €237.80, capping a week that saw the stock climb roughly 10%. The catalyst was a technological masterpiece from the company's New York lab: the world's first chip architecture that dips below the one-nanometer threshold. Yet beneath the surface of this rally lies a deep tension. The same week that IBM unveiled its 0.7nm Nanostack breakthrough, the IT consulting sector was rocked by Accenture's profit warning — a tremor that directly threatens the engine room of IBM's own services business.

The Nanostack chip is a genuine marvel. Its vertical stacking technique packs nearly 100 billion transistors onto an area the size of a fingernail, doubling transistor density compared to the previous generation. Performance can increase by up to 50%, or alternatively, energy consumption can shrink by 70% — a dual promise perfectly tuned for the voracious demands of AI workloads. IBM estimates that future AI accelerators based on this architecture could hit roughly 7,000 TOPS, a sharp jump from today's 1,500 TOPS. That could compress the training of complex AI models from three months to just two weeks.

But commercial reality intrudes. IBM does not mass-produce its own logic chips; it develops the architecture and licenses it to third-party foundries. No partner has yet been signed for the 0.7nm node, and engineers still wrestle with unresolved heat issues. The company itself says at least five years will pass before the technology reaches series production. In the near term, management is focused on scaling today's two-nanometer nanosheet technology. The Nanostack is a story for 2031 and beyond — not for next quarter's earnings call.

Investors are thus left to judge IBM on the here and now, and the here and now is dominated by a consulting slowdown. Mid-June, Accenture slashed its guidance, igniting fears that corporate IT spending is losing momentum. That matters enormously for IBM because its consulting arm carries a huge chunk of the company's generative AI contract backlog. The stock remains nearly 19% below its 52-week high from early June — evidence that even a historic chip announcement could not fully erase the sting of the Accenture shock.

Should investors sell immediately? Or is it worth buying IBM?

That dual reality is forcing market participants to differentiate. Software, which accounts for only 45% of IBM's revenue, generates roughly two-thirds of the group's profit. JPMorgan analyst Brian Essex argues this profit shift justifies a higher valuation. He points to concrete second-half drivers: Red Hat migration, stronger AI container adoption, and a 48% jump in mainframe revenue from IBM's latest line, as customers rush to bring AI-capable systems in-house. The recent partnership with ServiceNow will also bring joint solutions to market in the second half, providing an early gauge of software's ability to shrug off consulting headwinds.

Optimists also see a tailwind from public coffers. IBM is receiving $1 billion from a U.S. government initiative for quantum computing, and together with the Department of Commerce, it is building America's first pure quantum foundry, named Anderon. Both parties are committing $1 billion each to the venture, which will act as a neutral contract manufacturer for quantum chips. IBM plans to deliver error-free quantum systems by 2033.

Yet the bear case is stubborn. A study from IBM's own Institute for Business Value reveals that 91% of executives do not fully understand their AI dependencies, and 71% fear being locked into a single vendor. Analysts warn that complex integration hurdles could delay widespread AI adoption, throttling the monetization of IBM's Watsonx platform. If consulting weakness bleeds into software sales, the chip fantasy will provide little support. The stock's annualized 30-day volatility of nearly 70% underscores how skittish the market has become.

IBM at a turning point? This analysis reveals what investors need to know now.

The next hard reckoning comes on July 22, when IBM reports second-quarter earnings. Consensus calls for revenue of roughly $17.8 billion and earnings per share of $2.98. The numbers will answer the question that the Nanostack hype cannot: Can IBM's software engine accelerate fast enough to leave its consulting drag behind? Until then, the 200-day moving average at €235.90 serves as a key technical support — one that the stock only just reclaimed.

Ad

IBM Stock: New Analysis - 28 June

Fresh IBM information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated IBM analysis...

en | US4592001014 | IBMS | boerse | 69643006 |